Susy Chen, MD

Articles by Susy Chen, MD

Cost-Effectiveness of Extended-Release Carbidopa-Levodopa for Advanced Parkinson's Disease

ByRenée J.G. Arnold, PharmD, RPh,Andrew Layton, BA,Nathan R. Rustay, PhD,Susy Chen, MD

February 21st 2017

Existing levodopa therapies for Parkinson’s disease often provide inadequate symptom control after prolonged treatment. This study assessed the cost-effectiveness of an extended-release carbidopa-levodopa formulation (IPX066).

Latest Updated Articles

Cost-Effectiveness of Extended-Release Carbidopa-Levodopa for Advanced Parkinson's Disease
Published: February 21st 2017 | Updated:

Susy Chen, MD

Articles by Susy Chen, MD

Cost-Effectiveness of Extended-Release Carbidopa-Levodopa for Advanced Parkinson's Disease

Latest Updated Articles

Trending on Pharmacy Times

Breaking News: CVS Buys Rite Aid, Bartell Drugs

Amivantamab for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer

Young Women With Symptomatic Long COVID At Higher Risk of POTS

FDA Approves 1-Minute HIV Self-Test

Kellermensch: Living With the Emotional Weight of a Career in Health Care